Dr. Shah is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
400 Parnassus Ave
Fl 4
San Francisco, CA 94143Phone+1 415-353-9364Fax+1 415-353-6370
Education & Training
- University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2007 - 2010
- New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2002 - 2005
- New York University School of MedicineClass of 2002
Certifications & Licensure
- CA State Medical License 2016 - 2026
- TX State Medical License 2007 - 2017
Clinical Trials
- MM CAR-T to Upgrade Response BMTCTN1902 Start of enrollment: 2022 Jan 05
Roles: Contact
Publications & Presentations
PubMed
- 1 citationsMinimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Te...Marcelo C Pasquini, Paul K Wallace, Brent Logan, Manmeet Kaur, Joseph D Tario
Journal of Clinical Oncology. 2024-08-10 - 77 citationsStandardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transpla...Mohamed A. Kharfan-Dabaja, Ambuj Kumar, Ernesto Ayala, Mahmoud Aljurf, Taiga Nishihori
Transplantation and Cellular Therapy. 2021-08-01 - 31 citationsOutcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell TransplantationSyed Mohammad Ali Kazmi, Maliha Nusrat, Hilal Gunaydin, Amanda Cornelison, Nina Shah
Clinical Lymphoma, Myeloma & Leukemia. 2013-11-15
Journal Articles
- Primary Plasma Cell Leukemia: Autologous Stem Cell Transplant in an Era of Novel Induction DrugsKrina Patel, Rohtesh Mehta, Donna M Weber, Sheeba K Thomas, Nina Shah, Hans C Lee, Elisabet E Manasanch, Muzaffar H Qazilbash, Qaiser Bashir, Simrit Parmar, Robert Z O..., Nature
Abstracts/Posters
- Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell TherapyNina D. Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnose...Nina D. Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Breaking the Glass Ceiling of Age in Transplant in Multiple MyelomaNina D. Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 As a Single Agent in Relapsed or Refractory Hematologic Malignancies and in C...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Immunotherapy in Myeloma61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Daratumumab (DARA) Plus Lenalidomide Versus Lenalidomide Alone As Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma (NDMM) after Frontline Autolo...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Press Mentions
- CAR T-cell Therapy Produces Deep, Sustained Remissions in Patients with Relapsed MyelomaFebruary 24th, 2021
- Dr. Shah Discusses Data on Ide-Cel and Melflufen, Both Granted Priority Review by FDAOctober 23rd, 2020
- New Class of Drug Appears to Extend Survival in Patients with Triple-Refractory Multiple MyelomaJuly 30th, 2020
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: